AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23974954 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus Azathioprine
Number of subjects: 508
Study 23974954 — intervention group
Group type: COMPARATOR
Intervention: CDAI (cut-off 150)
Number of subjects: 508
Study 22819313 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended PLND
Number of subjects: 360
Study 22819313 — intervention group
Group type: COMPARATOR
Intervention: Standard PLND
Number of subjects: 360
Study 20537746 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50mg twice-daily
Number of subjects: 202
Study 20537746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 18714075 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (PDA) regarding the use of natural health products (NHPs)
Number of subjects: 90
Study 18714075 — intervention group
Group type: COMPARATOR
Intervention: General information brochure about menopause
Number of subjects: 90
Study 16149743 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula fortified with NT at 34 mg/L
Number of subjects: 200
Study 16149743 — intervention group
Group type: COMPARATOR
Intervention: Control formula with an innate level of NT at 10 mg/L
Number of subjects: 200
Study 16149743 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants (reference group)
Number of subjects: 200
Study 14648962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavilon No Sting Barrier Film (NSBF) applied to wound edges
Number of subjects: 227
Study 14648962 — intervention group
Group type: COMPARATOR
Intervention: Control (water) applied to wound edges
Number of subjects: 227
Study 14648962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavilon No Sting Barrier Film (NSBF)
Number of subjects: 227
Study 10565626 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment for 30 days
Number of subjects: 38
Study 10565626 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 38
Study 10565626 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (8 subjects)
Number of subjects: 38
Study 8706481 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ARDS
Number of subjects: 12
Study 8706481 — intervention group
Group type: COMPARATOR
Intervention: Control patients without lung injury
Number of subjects: 12
Study 1651857 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-burst stimulation (DBS)
Number of subjects: 90
Study 1651857 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical criteria (CC) and manual evaluation of TOF
Number of subjects: 90
Study 1651857 — intervention group
Group type: COMPARATOR
Intervention: Clinical criteria (CC) only
Number of subjects: 90
Study 7034669 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy and occupational therapy in the stroke unit
Number of subjects: 0
Study 7034669 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy and occupational therapy in medical units
Number of subjects: 0
Study 31256761 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan C (standard rapid rehydration using Ringer's lactate 100 ml/kg over 3 hours, incorporating 0.9% saline boluses for children with shock)
Number of subjects: 122
Study 31256761 — intervention group
Group type: COMPARATOR
Intervention: Slow rehydration (100 ml/kg Ringer's lactate over 8 hours without boluses)
Number of subjects: 122
Study 31256761 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan C
Number of subjects: 122
Study 31256761 — intervention group
Group type: COMPARATOR
Intervention: Slow rehydration
Number of subjects: 122
Study 31256761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 122
Study 30095637 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium bromide/salbutamol sulfate (COM)
Number of subjects: 0
Study 30095637 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 0
Study 30095637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30095637 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol sulfate (VEN)
Number of subjects: 0
Study 27255588 — intervention group
Group type: EXPERIMENTAL
Intervention: smalltalk group‐only program
Number of subjects: 2186
Study 27255588 — intervention group
Group type: EXPERIMENTAL
Intervention: smalltalk plus (group program plus home coaching)
Number of subjects: 2186
Study 27255588 — intervention group
Group type: COMPARATOR
Intervention: standard care (control)
Number of subjects: 2186
Study 24821196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine hydrochloride (50 mg)
Number of subjects: 20
Study 24821196 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 20
Study 22759785 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice (intervention group)
Number of subjects: 138
Study 22759785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary advice)
Number of subjects: 138
Study 19740900 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab every 6 weeks (Q6)
Number of subjects: 230
Study 19740900 — intervention group
Group type: COMPARATOR
Intervention: Infliximab on demand (DEM)
Number of subjects: 230
Study 17667569 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE for rocuronium
Number of subjects: 55
Study 17667569 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE for suxamethonium
Number of subjects: 55
Study 17667569 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE for morphine
Number of subjects: 55
Study 17667569 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE for pholcodine
Number of subjects: 55
Study 17667569 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis for rocuronium
Number of subjects: 55
Study 17667569 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis for suxamethonium
Number of subjects: 55
Study 17667569 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis for morphine
Number of subjects: 55
Study 17667569 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis for pholcodine
Number of subjects: 55
Study 17667569 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE inhibition tests
Number of subjects: 55
Study 17667569 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgE analysis
Number of subjects: 55
Study 16401960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (13 fractions, 3.0 Gy per fraction, and 4 fractions at 4.5 Gy per fraction, total dose of 57 Gy)
Number of subjects: 22
Study 16401960 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (37 fractions, 2.0 Gy per fraction, total dose of 74 Gy)
Number of subjects: 22
Study 16401960 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment, but included in the study)
Number of subjects: 22
Study 12417069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemocoagulase
Number of subjects: 180
Study 12417069 — intervention group
Group type: EXPERIMENTAL
Intervention: Lizhixue
Number of subjects: 180
Study 12417069 — intervention group
Group type: COMPARATOR
Intervention: Manitol hexanitrate
Number of subjects: 180
Study 12417069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemocoagulase and Lizhixue
Number of subjects: 180
Study 10613619 — intervention group
Group type: EXPERIMENTAL
Intervention: 100‐mg enteric‐coated diclofenac tablets
Number of subjects: 120
Study 10613619 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g acetaminophen
Number of subjects: 120
Study 10613619 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g acetaminophen plus 60 mg codeine
Number of subjects: 120
Study 10613619 — intervention group
Group type: EXPERIMENTAL
Intervention: 100‐mg enteric‐coated diclofenac tablets plus 1 g acetaminophen
Number of subjects: 120
Study 10613619 — intervention group
Group type: EXPERIMENTAL
Intervention: 100‐mg enteric‐coated diclofenac tablets plus 1 g acetaminophen plus 60 mg codeine
Number of subjects: 120
Study 10613619 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen plus codeine
Number of subjects: 120
Study 10613619 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 120
Study 7864704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg single dose
Number of subjects: 970
Study 7864704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg BID for 7 days
Number of subjects: 970
Study 7864704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg BID for 3 days
Number of subjects: 970
Study 7864704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg BID for 3 days
Number of subjects: 970
Study 7864704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg once daily for 3 days
Number of subjects: 970
Study 7864704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg once daily for 5 days
Number of subjects: 970
Study 7864704 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin 400 mg BID for 7 days
Number of subjects: 970
Study 2022937 — intervention group
Group type: EXPERIMENTAL
Intervention: Office cholesterol testing (study group)
Number of subjects: 4
Study 2022937 — intervention group
Group type: COMPARATOR
Intervention: No office cholesterol testing (control group)
Number of subjects: 4
Study 6804651 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% safflower oil emulsion
Number of subjects: 5
Study 6804651 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% safflower oil emulsion
Number of subjects: 5
Study 6804651 — intervention group
Group type: COMPARATOR
Intervention: Control (10% safflower oil emulsion)
Number of subjects: 5
Study 29040946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 108
Study 29040946 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 108
Study 27633391 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet intervention
Number of subjects: 980
Study 27633391 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 980
Study 27633391 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glutamate levels
Number of subjects: 980
Study 27633391 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glutamine-to-glutamate ratio
Number of subjects: 980
Study 27633391 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in metabolites after 1 year
Number of subjects: 980
Study 26386799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 952
Study 26386799 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 952
Study 26386799 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 952
Study 24163292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pesinet programme (telehealth service)
Number of subjects: 180
Study 24163292 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 180
Study 20691824 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells
Number of subjects: 87
Study 20691824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 17703100 — intervention group
Group type: EXPERIMENTAL
Intervention: *B/*C genotype (high ACP1 activity)
Number of subjects: 300
Study 17703100 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 300
Study 16794028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (3 h/day, 5 days/wk at 4,000‐5,500 m)
Number of subjects: 23
Study 16794028 — intervention group
Group type: COMPARATOR
Intervention: Normoxic (placebo)
Number of subjects: 23
Study 12880731 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana leaf dressing (BLD)
Number of subjects: 30
Study 12880731 — intervention group
Group type: COMPARATOR
Intervention: Boiled potato peel bandage (BPPB)
Number of subjects: 30
Study 11199613 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based composite restorations
Number of subjects: 0
Study 11199613 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 0
Study 9058224 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 0.25% bupivacaine
Number of subjects: 135
Study 9058224 — intervention group
Group type: COMPARATOR
Intervention: NaCl (control)
Number of subjects: 135
Study 8382840 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-8 at a concentration of 10 nm
Number of subjects: 8
Study 8382840 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals and MDS patients)
Number of subjects: 8
Study 3959564 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor identified as a recovering alcoholic
Number of subjects: 42
Study 3959564 — intervention group
Group type: COMPARATOR
Intervention: Counselor not identified as a recovering alcoholic
Number of subjects: 42
Study 30273892 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed women with childhood emotional abuse
Number of subjects: 52
Study 30273892 — intervention group
Group type: COMPARATOR
Intervention: Depressed women without childhood emotional abuse
Number of subjects: 52
Study 30273892 — intervention group
Group type: COMPARATOR
Intervention: Never-depressed women without childhood emotional abuse
Number of subjects: 52
Study 26714202 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI treatment (escitalopram or sertraline)
Number of subjects: 1008
Study 26714202 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRI treatment (venlafaxine)
Number of subjects: 1008
Study 25109096 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who experienced IPV
Number of subjects: 2621
Study 25109096 — intervention group
Group type: COMPARATOR
Intervention: Women who did not experience IPV
Number of subjects: 2621
Study 23650968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 200 μg/100 μl
Number of subjects: 24
Study 23650968 — intervention group
Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC) 200 µg
Number of subjects: 24
Study 23650968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS)
Number of subjects: 24
Study 23650968 — intervention group
Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 24
Study 20603855 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial FOBT screening
Number of subjects: 105000
Study 20603855 — intervention group
Group type: COMPARATOR
Intervention: Control group (unscreened)
Number of subjects: 105000
Study 18256417 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii for five days in addition to oral rehydration solution (ORS)
Number of subjects: 100
Study 18256417 — intervention group
Group type: COMPARATOR
Intervention: ORS alone (control group)
Number of subjects: 100
Study 18256417 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 100
Study 16895629 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU of HCG (group 1, n = 15)
Number of subjects: 45
Study 16895629 — intervention group
Group type: COMPARATOR
Intervention: HCG 1500 IU, 12 h after ovulation induction (group 2, n = 17)
Number of subjects: 45
Study 16895629 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG 1500 IU 35 h after ovulation induction (group 3, n = 13)
Number of subjects: 45
Study 14626378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) after local excision (LE)
Number of subjects: 0
Study 14626378 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision (LE) with margin width > or = 1 cm
Number of subjects: 0
Study 14626378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 14626378 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-sparing mastectomy (SSM) with autologous myocutaneous flap reconstruction
Number of subjects: 0
Study 14626378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 0
Study 10776679 — intervention group
Group type: EXPERIMENTAL
Intervention: Before-Discharge Intervention Method (BDIM)
Number of subjects: 0
Study 10776679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BDIM)
Number of subjects: 0
Study 8636581 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial blood pressure changes
Number of subjects: 22
Study 8636581 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural blood pressure changes
Number of subjects: 22
Study 8636581 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial hypotension
Number of subjects: 22
Study 8636581 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic hypotension
Number of subjects: 22
Study 8636581 — intervention group
Group type: EXPERIMENTAL
Intervention: Both postprandial and orthostatic hypotension
Number of subjects: 22
Study 8636581 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular medications
Number of subjects: 22
Study 8636581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-class correlation of postprandial systolic BP
Number of subjects: 22
Study 8636581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-class correlation of postural systolic BP
Number of subjects: 22
Study 1336356 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I, insulin‐dependent diabetic subjects with microalbuminuria
Number of subjects: 34
Study 1336356 — intervention group
Group type: COMPARATOR
Intervention: Normoalbuminuric type I, insulin‐dependent diabetic subjects
Number of subjects: 34
Study 1336356 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study 2866786 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 50, 100 and 200 mg
Number of subjects: 7
Study 2866786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 40, 80 and 160 mg
Number of subjects: 7
Study 2866786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2866786 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 200 mg
Number of subjects: 7
Study 31370791 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 31370791 — intervention group
Group type: COMPARATOR
Intervention: Confidence interval/band based approaches
Number of subjects: 0
Study 29206782 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 16
Study 29206782 — intervention group
Group type: COMPARATOR
Intervention: Control Group (C)
Number of subjects: 16
Study 25301896 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3 (‐) supplementation (beetroot juice, 8.2 mmol/day NO3 (‐))
Number of subjects: 8
Study 23734518 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 83
Study 23734518 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 83
Study 20307043 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-chop technique
Number of subjects: 102
Study 20307043 — intervention group
Group type: COMPARATOR
Intervention: Stop-and-chop technique
Number of subjects: 102
Study 16981899 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg of intravenous beclomethasone monopropionate (17-BMP) for 15 min
Number of subjects: 8
Study 16981899 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg of intravenous beclomethasone monopropionate (17-BMP) for 2 h
Number of subjects: 8
Study 16981899 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned in the abstract)
Number of subjects: 8
Study 15956631 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy based on coronary stenting with abciximab
Number of subjects: 365
Study 15956631 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment strategy
Number of subjects: 365
Study 15956631 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 365
Study 15956631 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 365
Study 14712987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine oestrogen, 0.625 mg/day
Number of subjects: 90
Study 14712987 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol patches, 50 microg/day
Number of subjects: 90
Study 14712987 — intervention group
Group type: COMPARATOR
Intervention: No hormones
Number of subjects: 90
Study 10737822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory urine drug screening
Number of subjects: 392
Study 10737822 — intervention group
Group type: COMPARATOR
Intervention: Usual-care (clinical judgment based)
Number of subjects: 392
Study 8855811 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol replacement therapy (micronized estradiol [Estrace TM], 2 mg orally each day)
Number of subjects: 37
Study 8855811 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 37
Study 8855811 — intervention group
Group type: COMPARATOR
Intervention: Both arms (estradiol and control)
Number of subjects: 37
Study 8855811 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol replacement therapy (in subset with less than 3 months of amenorrhea)
Number of subjects: 37
Study 8855811 — intervention group
Group type: COMPARATOR
Intervention: No therapy (in subset with greater than 3 months of amenorrhea)
Number of subjects: 37
Study 1643806 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy living advice (diet and physical activity) over 6 months (n = 23)
Number of subjects: 31
Study 1643806 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy living advice (diet and physical activity) over 2 years (n = 17 reassessed)
Number of subjects: 31
Study 1643806 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8, 7 examined)
Number of subjects: 31
Study 6379570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefamandole, 1.5 g before incision followed by 1.5 g every four hours up to the 24th postoperative hour
Number of subjects: 84
Study 6379570 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (control group K-)
Number of subjects: 84
Study 31045590 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (3000 mg/d)
Number of subjects: 38
Study 31045590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 28626868 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 90
Study 28626868 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg meperidine
Number of subjects: 90